logo
How to Cut Costs in the Right Places and Do More With Less

How to Cut Costs in the Right Places and Do More With Less

Entrepreneur15-07-2025
In this time of stress for many small businesses, thoughtful cost-cutting can make your company leaner, more agile and scalable without sacrificing long-term growth.
Opinions expressed by Entrepreneur contributors are their own.
If you're a small business owner right now, you're probably feeling the tension in the market. There is immense pressure to grow, serve your clients, pay your team and still keep a healthy margin against the background of a turbulent economy. At the same time, you know you can't just slash costs blindly, as cutting the wrong things can put you in an even more difficult position.
Done well, strategic cost-cutting can actually make your business leaner, more agile and more scalable — and it can give you increased peace of mind. Instead of running your business from a place of fear, reframe this time as a way to lean out your business and build a stronger foundation. You may be surprised at how you'll run just as effectively with less.
Related: 5 Ways to Cut Costs in Your Business
Understanding your costs comes first
Studies show that a large portion of small business owners are not aware of their key expenses. Before cutting anything, it is critical to zoom out and get a handle on where your money is actually going.
Labor is commonly the largest expense for small businesses. If you don't already have clear ROI data on your team's time, now is the time to set it up. These ROI calculations can vary drastically depending on the role, so if you have KPIs set up, take this time to review those. If you don't, I'd recommend working with a strategic finance specialist to set those up.
Regardless, looking at your revenue per FTE (full-time employee) is a good place to start. That KPI should be close to $500,000 per full-time employee. If you are coming in under that, start looking at where on your team you can redirect their time to be revenue-generating or reduce labor time and cost.
Other expenses that tend to be fairly easy to reduce include outside contractor expenses, unused subscriptions and travel expenses. It's a wise practice to review these expenses, one by one, every single month.
This kind of detailed financial review can be intimidating and stressful, but it is absolutely critical to surviving a slowdown as a small business. By establishing this practice now, you're also creating a strong habit of being financially smart inside your business.
Related: Don't Let These 8 Common Expenses Stunt Your Growth and Drain Your Profits
Considering what and when to delegate
A common myth is that delegation always saves you time, but that doesn't always play out. It can become costly if done wrong, and any delegation you're currently doing is worth a second look.
There are a few things to consider when evaluating what you're already delegating or if you're considering newly delegating work.
First, delegation works best if you've already systematized what's being handed off. If you systematize first, you are delegating something that will minimize the cost of delegated labor, so you're maximizing your ROI. This can look like automation inside of your CRM or creating SOPs for your main practices.
Speaking of ROI, consider the ROI of anything you're paying to delegate. As an example, if you're outsourcing cold-calling your leads, consider the cost of each call based on the hourly rate you're paying and the number of appointments generated. This gives you an estimate of the cost per appointment, which helps you understand the ROI of that investment. If you can invest the money elsewhere in your business with a better return, this is the time to shift that investment.
Related: 8 Unconventional Ways to Cut Costs in Your Business
Don't cut where it counts
Most businesses will go wrong by cutting investments that actually support long-term growth, like marketing, client delivery support or team culture, when they start feeling the financial pinch.
It's critical to examine the ROI of each cost instead of panic-cost cutting. If your assistant is saving you 10 hours a week and you're using that time to close deals, that has its own return. If your operations manager is helping you retain key clients, that's a return. Make your best estimate of what that return is to help guide you in making that comparison. For your assistant, count the value of the deals they helped you close. For your manager, consider how many key clients they've helped re-sign.
One effective way to avoid this is to reinvest more into client delivery for your existing clients rather than growth. By ensuring your client delivery is top-notch, you can shore up growth by creating fans who will then refer to you while better retaining your existing clients. This can give you a multi-faceted return on the same investment.
Despite the slowdown that many small businesses are feeling in real-time, the goal at this moment in time isn't just to survive. Rather, it's to build a business that's effective and lean. Then, when the economy inevitably picks back up, you've built an efficient business to build on, and you've flexed the muscles of regularly monitoring your finances and making data-driven decisions about them.
Join top CEOs, founders and operators at the Level Up conference to unlock strategies for scaling your business, boosting revenue and building sustainable success.
Orange background

Try Our AI Features

Explore what Daily8 AI can do for you:

Comments

No comments yet...

Related Articles

Why Google should 'walk away' from Waymo
Why Google should 'walk away' from Waymo

Yahoo

time16 minutes ago

  • Yahoo

Why Google should 'walk away' from Waymo

Needham & Company senior media and internet analyst Laura Martin joins Market Domination with Josh Lipton to explain why Alphabet (GOOG, GOOGL) should ditch Waymo and focus on generative artificial intelligence (AI) instead. To watch more expert insights and analysis on the latest market action, check out more Market Domination here. Related videos The £70bn pension tax raid Reeves may not be able to resist 10 shares I wouldn't want to hold in a stock market crash After falling 16% in a day, this stock's on my list of shares to buy in August This FTSE 250 trust is easily beating the global index in 2025. Time to buy? Sign in to access your portfolio

EMCOR Group (EME) Sees EPS Surge as Net Income Climbs to US$241 Million
EMCOR Group (EME) Sees EPS Surge as Net Income Climbs to US$241 Million

Yahoo

time16 minutes ago

  • Yahoo

EMCOR Group (EME) Sees EPS Surge as Net Income Climbs to US$241 Million

EMCOR Group recently announced a regular quarterly cash dividend of $0.25 per common share, to be paid on July 31, 2025. This steady dividend approach aligns with the company's robust quarterly performance, which saw net income rise to $241 million and EPS increase substantially year-over-year. Additionally, the ongoing share buyback program has strengthened shareholder returns. Despite the broader market's moderate growth of 1.4% over the past week and 17% over the past year, EMCOR's notable share repurchases and solid financial outcomes appear to have amplified investor confidence, contributing to the company's impressive 55% stock price surge last quarter. We've spotted 1 risk for EMCOR Group you should be aware of. Trump has pledged to "unleash" American oil and gas and these 22 US stocks have developments that are poised to benefit. EMCOR Group's recent announcement of a quarterly dividend and the implementation of its share buyback program underline its commitment to enhancing shareholder returns. Despite a potential downside to the current share price of US$635.06, which exceeds the consensus analyst price target of US$549.57 by 13.46%, these actions could continue to buoy investor confidence. The company's performance over the past five years, with a total return exceeding 844.60%, showcases its robust long-term trajectory. In the last year, EMCOR's share performance exceeded both the broader market's 17.2% and the US Construction industry's 54.2% return, highlighting its strong standing relative to peers. The successful integration of acquisitions and strategic diversification into sectors like data centers and healthcare is anticipated to impact future revenue positively. This, coupled with operational efficiencies and strong revenue collaboration, may reinforce earnings projections. However, EMCOR's earnings forecasts of a 6.2% annual growth rate lag behind the broader market's 14.9% forecast, which could present challenges in meeting broader industry expectations. The company's impressive share price rise of 55% last quarter signals optimism, though its current value being above the target may indicate overvaluation concerns. Nevertheless, the consistent cash flow and healthy margins underscore its potential resilience against margin pressures, supply chain challenges, and other economic uncertainties. As analysts estimate revenue growth to 7.9% annually over the next three years, any tangible improvement in operational metrics could shift the valuation outlook positively. Unlock comprehensive insights into our analysis of EMCOR Group stock in this financial health report. This article by Simply Wall St is general in nature. We provide commentary based on historical data and analyst forecasts only using an unbiased methodology and our articles are not intended to be financial advice. It does not constitute a recommendation to buy or sell any stock, and does not take account of your objectives, or your financial situation. We aim to bring you long-term focused analysis driven by fundamental data. Note that our analysis may not factor in the latest price-sensitive company announcements or qualitative material. Simply Wall St has no position in any stocks mentioned. Companies discussed in this article include EME. This article was originally published by Simply Wall St. Have feedback on this article? Concerned about the content? with us directly. Alternatively, email editorial-team@ Error in retrieving data Sign in to access your portfolio Error in retrieving data Error in retrieving data Error in retrieving data Error in retrieving data

Pfizer (PFE) Receives CHMP Recommendation For Adapted COVID-19 Vaccine COMIRNATY
Pfizer (PFE) Receives CHMP Recommendation For Adapted COVID-19 Vaccine COMIRNATY

Yahoo

time16 minutes ago

  • Yahoo

Pfizer (PFE) Receives CHMP Recommendation For Adapted COVID-19 Vaccine COMIRNATY

BioNTech SE and Pfizer recently received a positive recommendation from the European Medicines Agency for marketing authorization of their COVID-19 vaccine, which likely contributed to Pfizer's share price increase of 8% in the last quarter. The company's advancements in COVID-19 vaccine development, alongside other product-related announcements like the XTANDI and BRAFTOVI trial results, added weight to this upward movement. Despite legal challenges and declining earnings, Pfizer's focus on innovation and strategic partnerships like the one with XtalPi possibly countered broader market moves, which saw a smaller 1% increase in the same period. We've identified 3 warning signs for Pfizer that you should be aware of. Trump's oil boom is here — pipelines are primed to profit. Discover the 22 US stocks riding the wave. The recent positive recommendation from the European Medicines Agency for the COVID-19 vaccine developed by BioNTech SE and Pfizer has contributed to an 8% increase in Pfizer's share price over the last quarter. This news may provide a temporary boost to Pfizer's revenue and earnings forecasts, especially as the company continues to innovate amidst legal challenges and declining earnings. The authorization could enhance immediate market confidence in Pfizer's product pipeline, impacting future revenue projections positively. Over the past year, Pfizer experienced a total return of 13.78% including dividends, reflecting a challenging period for shareholders. When compared to the broader US market's return of 17.2% over the same period, Pfizer has underperformed, highlighting investor concerns over competitive pressures and revenue growth prospects. The current share price movement toward the analyst consensus price target of $29.23 suggests a cautiously optimistic outlook among some market participants. Analysts' revenue forecasts reflect potential declines due to increased competition for existing products, yet others anticipate that strategic shifts in research focus, especially in oncology, might mitigate future earnings risks. With a modest increase of 8% in shares largely tied to vaccine authorization, it underscores the uncertainty surrounding longer-term performance relative to bearish analyst expectations. Understand Pfizer's track record by examining our performance history report. This article by Simply Wall St is general in nature. We provide commentary based on historical data and analyst forecasts only using an unbiased methodology and our articles are not intended to be financial advice. It does not constitute a recommendation to buy or sell any stock, and does not take account of your objectives, or your financial situation. We aim to bring you long-term focused analysis driven by fundamental data. Note that our analysis may not factor in the latest price-sensitive company announcements or qualitative material. Simply Wall St has no position in any stocks mentioned. Companies discussed in this article include PFE. This article was originally published by Simply Wall St. Have feedback on this article? Concerned about the content? with us directly. Alternatively, email editorial-team@

DOWNLOAD THE APP

Get Started Now: Download the App

Ready to dive into a world of global content with local flavor? Download Daily8 app today from your preferred app store and start exploring.
app-storeplay-store